Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: A meta-analysis of randomized controlled trials.

Cilostazol: A New Oasis for Coronary Artery Disease Management

Coronary artery disease (CAD), a leading cause of heart disease, often requires the use of drug-eluting stents (DESs) to restore blood flow. This study investigated the long-term clinical efficacy and safety of adding cilostazol, a drug that inhibits platelet aggregation, to conventional dual antiplatelet therapy (DAT) for patients undergoing DES implantation.

Strengthening the Guard: Cilostazol and Coronary Artery Disease Management

The meta-analysis of seven randomized controlled trials revealed that adding cilostazol to DAT significantly reduced the risk of major adverse cardiac events (MACEs), target lesion revascularization (TLR), and in-stent restenosis. This suggests that cilostazol can be a valuable addition to the standard treatment regimen for patients undergoing DES implantation, providing a more robust approach to managing CAD.

A More Robust Approach to CAD Management

The research suggests that cilostazol, like a resourceful traveler in the desert, can enhance the effectiveness of standard treatment regimens for CAD. By adding an extra layer of protection, cilostazol may help prevent complications and improve long-term outcomes for patients. It's like finding a hidden spring of protection, contributing to a more resilient and stable cardiovascular system.

Dr.Camel's Conclusion

This study demonstrates the potential of cilostazol to enhance the long-term management of coronary artery disease. It's a reminder that a multi-faceted approach to treatment, like finding multiple oases in a vast desert, can lead to better outcomes and improved quality of life for patients.